Icosapent Ethyl
- Generic Name
- Icosapent Ethyl
- Brand Names
- Vascepa, Vazkepa
- Drug Type
- Small Molecule
- Chemical Formula
- C22H34O2
- CAS Number
- 86227-47-6
- Unique Ingredient Identifier
- 6GC8A4PAYH
- Background
Icosapent ethyl or ethyl eicosapentaenoic acid is a synthetic derivative of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. FDA approved on July 26, 2012.
- Indication
作为最大耐受他汀类药物治疗的辅助手段，以降低甘油三酯（TG）水平升高（≥150mg/dL）、已确定的心血管疾病或糖尿病以及2个或更多心血管疾病风险因素的成年患者需要住院治疗的心肌梗死、中风、冠状动脉血运重建和不稳定心绞痛的风险。
- Associated Conditions
- Hospitalizations, Severe Hypertriglyceridemias
- Associated Therapies
- -
IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2024-06-20
- Target Recruit Count
- 110
- Registration Number
- NCT06466278
- Locations
- 🇳🇱
Academic Medical Center, Amsterdam, Netherlands
Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 200
- Registration Number
- NCT06280976
- Locations
- 🇺🇸
University of Louisville School of Medicine, Division of Cardiovascular Diseases, Louisville, Kentucky, United States
A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults
- Conditions
- Interventions
- First Posted Date
- 2020-08-10
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Kaiser Permanente
- Target Recruit Count
- 39600
- Registration Number
- NCT04505098
- Locations
- 🇺🇸
Division of Research, Oakland, California, United States
An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
- First Posted Date
- 2020-06-02
- Last Posted Date
- 2021-12-22
- Target Recruit Count
- 100
- Registration Number
- NCT04412018
- Locations
- 🇨🇦
North York Diagnostic and Cardiology Clinic, Toronto, Ontario, Canada
Efficacy of Ethyl Icosapentate in Patients With Severe Hypertriglyceridemia
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Mochida Pharmaceutical Company, Ltd.
- Target Recruit Count
- 316
- Registration Number
- NCT04239950
- Locations
- 🇨🇳
Mochida Investigational sites, Changsha, China
Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
- Conditions
- Interventions
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04177680
- Locations
- 🇺🇸
Matinas Investigational Site, Chicago, Illinois, United States
🇺🇸Matinas Investigational site, Richmond, Virginia, United States
EPA for Metastasis Trial 2
- Conditions
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Mark A Hull, PhD FRCP
- Target Recruit Count
- 418
- Registration Number
- NCT03428477
- Locations
- 🇬🇧
University Hospital of Wales, Cardiff, United Kingdom
🇬🇧Cambridge UniversityHospitals NHS Foundation Trust, Cambridge, United Kingdom
🇬🇧Aintree University Hospitals NHS Foundation Trust, Aintree, United Kingdom
Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
- First Posted Date
- 2016-10-20
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT02940223
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2023-02-21
- Target Recruit Count
- 80
- Registration Number
- NCT02926027
- Locations
- 🇺🇸
Intermountain Medical Center, Intermountain Heart Institute, Murray, Utah, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center (The Lundquist Institute), Torrance, California, United States
Effects of Eicosapentaenoic Acid on Endothelial Function in Diabetic Subjects
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2022-03-18
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 2
- Registration Number
- NCT02422446
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.